Anti-RNase L – Purified in vivo GOLD™ Functional Grade

Anti-RNase L – Purified in vivo GOLD™ Functional Grade

Product No.: R6000

[product_table name="All Top" skus="C2859"]

- -
- -
Clone
2E9
Target
RNaseL
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
2',5'-oligoisoadenylate synthetase-dependent; 2-5A-dependent ribonuclease; 2-5A-dependent RNase; interferon-induced 2-5A-dependent RNase; Ribonuclease 4; Ribonuclease L; ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent); ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent); RNase L; PRCA1; RNS4
Isotype
Mouse IgG1 κ
Applications
ELISA
,
IHC FFPE
,
in vivo
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Hamster
Human
Primate
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Purified, full-length, recombinant, human RNaseL produced in insect cells.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
WB
ELISA
Additional Applications Reported In Literature ?
IHC FFPE
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 2E9 recognizes an epitope on human/hamster/primate RNaseL.
Background
RNase L antibody, clone 2E9, recognizes the interferon (IFN)-inducible 2-5A-dependent ribonuclease L (RNase L), an endoribonuclease involved in antiviral signaling. It is widely expressed as a latent monomer in most mammalian tissues1. 2’,5’-oligoadenylate synthetase (OAS) is expressed following viral infection and exposure to IFN2. OAS proteins are activated by dsRNA, resulting in the production of 2’,5’-linked oligoadenylates (2-5A), which bind to latent RNase L, inducing dimerization and activation2. RNase L inhibits viral replication by cleaving viral and ribosomal RNA3,4 and inducing apoptosis in virus-infected cells5,6. RNase L is suggested to have antitumor effects, possibly through its pro-apoptotic activity7, and mutations in the RNASEL gene are associated with prostate cancer risk and progression8,9.
Antigen Distribution
RNase L is highly expressed in the spleen and thymus, followed by prostate, testis, uterus, small intestine, colon, and peripheral blood leukocytes.
PubMed
NCBI Gene Bank ID
Research Area
Cell Biology
.
Immunology
.
Neuroinflammation
.
Neuroscience

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Based on the available search results, clone 2E9 refers to multiple different antibodies targeting various proteins, making it challenging to identify specific in vivo applications in mice for a single clone 2E9. However, the search results provide limited direct information about in vivo mouse applications.

Identified Clone 2E9 Antibodies

The search results reveal several distinct antibodies designated as clone 2E9, each targeting different proteins:

Anti-Amyloid beta A4 protein (APP) - This rat monoclonal antibody detects multiple isoforms of APP and targets an 11 amino acid sequence in the C-terminal region. The antibody shows reactivity with both mouse and human species, though the search results do not describe specific in vivo mouse applications.

Anti-LAT antibody - A mouse monoclonal antibody targeting LAT (Linker for Activation of T cells) validated for immunoprecipitation and Western blot applications. However, no in vivo mouse studies are mentioned in the available information.

Anti-pig SLA Class II DR - This mouse monoclonal antibody recognizes swine leukocyte antigen molecules and inhibits mixed lymphocyte reactions. This antibody is specifically designed for porcine applications rather than mouse studies.

Limitations

The search results do not provide detailed information about common in vivo applications of any clone 2E9 antibody specifically in mouse models. While several clone 2E9 antibodies show mouse species reactivity, the available sources primarily describe in vitro applications such as immunoprecipitation, Western blotting, immunofluorescence, and immunohistochemistry rather than in vivo experimental uses in mice.

In the literature, several antibodies and proteins are commonly used alongside the 2E9 antibody, depending on the specific application and research area. Here are a few examples:

  1. Beta Amyloid 2E9 Antibody: This antibody is used for studying Alzheimer's disease, particularly in detecting amyloid-beta plaques in the brain. It is often used in conjunction with other antibodies that target different aspects of Alzheimer's pathology, such as tau proteins.

  2. EGFR 2E9 Antibody: This mouse monoclonal antibody targets the epidermal growth factor receptor (EGFR) and is commonly used in flow cytometry and immunocytochemistry for studying cell signaling pathways. It may be used with other antibodies targeting different receptors or proteins involved in cell signaling.

  3. Tau 2E9 Antibody: This antibody is used in neuroscience research, particularly for detecting tau proteins associated with neurodegenerative diseases like Alzheimer's. It might be used with other tau antibodies or those targeting amyloid-beta to study neurodegenerative disease mechanisms comprehensively.

  4. Secondary Antibodies: In many applications, secondary antibodies like goat anti-mouse IgG or rabbit anti-rat IgG are used to detect primary antibodies such as those labeled "2E9". These secondary antibodies are crucial for various immunological assays, providing a detectable signal through labels like HRP or fluorescent dyes.

In addition to these, proteins like actin or tubulin are often used as loading controls in Western blot experiments to ensure that equal amounts of protein are loaded across different samples.

Commonly Used Proteins for Controls:

  • Actin: Often used as a housekeeping protein to verify equal loading in Western blots.
  • Tubulin: Another common loading control used to confirm sample integrity and equal protein loading.

These proteins are typically used in various antibody-based assays to validate the effectiveness and specificity of the primary antibodies like the 2E9 series.

Clone 2E9 citations in scientific literature primarily refer to several different monoclonal antibodies, each targeting distinct proteins in diverse research contexts. The main scientific findings relate to antibody specificity, target detection, and their application in disease models and diagnostic assays.

Key findings associated with clone 2E9:

  • High specificity and sensitivity for target epitopes:
    For antibodies against phosphorylated TDP-43 (notably pS409/410-TDP-43), clone 2E9 demonstrates strong immunoreactivity and specificity, outperforming several other clones in ELISA, dot blot, and immunohistochemistry tests. This makes 2E9 particularly valuable for detecting pathological TDP-43 inclusions in frontotemporal lobar degeneration (FTLD-TDP) and ALS patient samples.

  • Utility in biomarker detection and controversy resolution:
    In the context of 15-keto-cholestane-22-oic acid (15-KA), recombinant antibody RAb2E9 was developed and validated for high-specificity detection in ELISA and confirmed by LC-MS. While sensitive, RAb2E9 was unable to detect 15-KA in EAE mouse serum, helping to clarify controversy over 15-KA as a multiple sclerosis biomarker by showing its undetectability in this context.

  • Diagnostic application for glycoprotein-specific antibodies:
    Clone 2E9 developed against glycosylated prostate-specific antigen (fuc-PSA) is highly specific for fucosylated forms, distinguishing them from total PSA. Its reactivity is dependent on both protein and glycan moieties, with no reactivity to deglycosylated PSA, indicating application potential in improved prostate cancer diagnostics by targeting specific glycoforms.

  • Other applications and targets:
    Clone 2E9 also appears as a monoclonal antibody for various proteins in commercial reagent catalogs, such as PPP1R2 (protein phosphatase 1 inhibitor 2), RNase L, and pig SLA class II DR for immunoprecipitation, emphasizing its recurrent use as a designation for well-characterized, target-specific monoclonal antibodies in both research and clinical assays.

Summary table of notable clone 2E9 citations:

Antibody TargetKey Application/InsightCitation
pS409/410-TDP-43Detects pathological TDP-43 inclusions in FTLD/ALS
15-Keto-cholestane-22-oic acid (15-KA)Sensitive ELISA/LC-MS biomarker validation; negative in EAE serum
Glycosylated PSA (fuc-PSA)Specific detection of fucosylated PSA for diagnostics
PPP1R2, RNase L, SLA class II DR, NFAM1Various research and diagnostic reagents (commercial supply)

When referencing "clone 2E9" in literature, check the specific target and context, as the designation is reused across distinct antibodies for different proteins. Citations consistently report high specificity and reliable detection within their validated applications.

The dosing regimens of clone 2E9 across different mouse models are not comprehensively detailed in available literature or dosing guides, and clone 2E9 is associated with several different targets depending on context (e.g., anti-SLA DR in pigs, anti-Tau in neurobiology, anti-beta amyloid). No authoritative dosing recommendations for clone 2E9 in mouse models are explicitly listed in the standard antibody dosing guides for in vivo studies.

Available context and related antibodies suggest the following principles:

  • If clone 2E9 is being used as an in vivo depleting monoclonal antibody (mAb) in mouse models, the typical dose range for mAbs with similar applications (e.g., anti-CD4 GK1.5, anti-CD8 2.43, anti-Gr-1 RB6-8C5) is usually 100–250 μg per mouse, delivered via intraperitoneal injection, with dosing intervals of every 2–4 days or 2–3 times per week.

  • For antibodies targeting T cell subsets, checkpoint blockade, or depletion (such as anti-CD4, anti-CD8, anti-CTLA-4, anti-PD-1), dosing regimens are chosen based on the desired immunological effect, model specifics (tumor vs infection vs autoimmunity), and antibody isotype, frequently within the above dose and schedule range.

  • If clone 2E9 is used for in vitro experiments (e.g., immunohistochemistry, flow cytometry), working concentrations are generally specified based on the application—for example, 1:1,000–1:2,000 dilution for immunohistochemistry or Western blot. These concentrations do not translate directly to in vivo dosing.

  • Regimen variation by mouse model is generally dictated by:

    • The disease model or immunological context (e.g., tumor, infection, transplantation).
    • The intended antibody effect (blockade vs depletion vs neutralization).
    • Mouse strain, age, and weight, although fixed dosing is frequently employed for monoclonal antibodies due to their wide therapeutic windows and target specificity.
  • Lack of direct published examples: No specific dosing schedules for clone 2E9 in mouse models could be identified in authoritative sources. If clone 2E9 is newly generated for a particular application or target, dosing should start with pilot titration studies using the above reference range for mAbs.

Summary Table: Reference Dosing for Mouse Monoclonal Antibodies in Vivo

AntibodyDose per MouseRouteIntervalApplication
GK1.5 (Anti-CD4)200-250 μgIntraperitoneal2–3 times per weekT cell depletion
2.43 (Anti-CD8)250 μgIntraperitoneal2–3 times per weekT cell depletion
9D9 (Anti-CTLA-4)100–250 μgIntraperitonealEvery 3 daysCheckpoint blockade
29F.1A12 (Anti-PD-1)100–200 μgIntraperitonealEvery 3 daysCheckpoint blockade

If you have a specific application, target, or disease model for clone 2E9, providing those details may allow for more tailored guidance. In summary, use established dosing regimens for similar monoclonal antibodies as a starting point until model-specific data for clone 2E9 is published.

References & Citations

1. Zhou A, et al. (2005) J Interferon Cytokine Res. 25(10):595-603
2. Silverman RH. (2007) Cytokine Growth Factor Rev. 18(5-6):381-8
3. Wreschner DH, et al. (1981) Nucleic Acids Res. 9(7):1571-81
4. Cooper DA, et al. (2014) Nucleic Acids Res. 42(8):5202-16
5. Castelli JC, et al. (1997) J Exp Med. 186(6):967-72
6. Zhou A, et al (1997) EMBO J. 16(21):6355-63
7. Xiang Y, et al. (2003) Cancer Res. 63(20):6795-801
8. Meyer MS, et al. (2010) Carcinogenesis. 31(9):1597-603
9. Silverman RH. (2003) Biochemistry. 42(7):1805-12
Indirect Elisa Protocol
IHC FFPE
in vivo Protocol
General Western Blot Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.